[Alloy Therapeutics in Business Wire] Alloy Therapeutics unveils 2023 innovation roadmap across antibodies, TCRs, bispecifics, and genetic medicines
BOSTON–(BUSINESS WIRE)–Alloy Therapeutics, a biotechnology ecosystem company, announced its 2023 roadmap of new discovery technologies and services across a range of biologic modalities. Alloy will support its community of 140+ partners with deepened capabilities in its core antibodies offering, as well as substantial expansion into new modalities such as genetic medicines, leveraging an existing partnership announced with Dr. Sudhir Agrawal, a pioneer of gapmer antisense oligonucleotide (ASO) technology. Read...
Read More